Acquisition History / Alivus Life Sciences / Iqgen-X

Alivus Life Sciences Acquires Iqgen-X

Announced August 18, 2026 — $1.0M

Alivus Life SciencesPharmaceuticals2026

What happened

Alivus Life Sciences acquired a 76% stake in Iqgen-X, an Indian pharmaceuticals business, for Rs 9.12 crore. The transaction is listed in PrivateCircle's August 2026 India acquisition roundup, drawn from company deal disclosures.

Acquirer
Alivus Life Sciences
Target
Iqgen-X
Announced
August 18, 2026
Price
$1.0M
Industry
Pharmaceuticals
Buyer type
Strategic acquirer
Status
Announced, not yet closed

By the numbers

Alivus Life Sciences's acquisition history
1st of 1 tracked deals
Disclosed prices
1 of 1 Alivus Life Sciences deals
Alivus Life Sciences's average disclosed price
$1.0M
Alivus Life Sciences's largest disclosed deal
Iqgen-X ($1.0M)
Tracked acquisitions in 2026
397 across all acquirers
Alivus Life Sciences in Pharmaceuticals
1 acquisition

Frequently Asked Questions About This Acquisition

When did Alivus Life Sciences acquire Iqgen-X?

Alivus Life Sciences acquired Iqgen-X on August 18, 2026. This was Alivus Life Sciences's 1st publicly tracked acquisition out of 1 we have on record.

How much did Alivus Life Sciences pay for Iqgen-X?

Alivus Life Sciences paid $1.0M for Iqgen-X.

What does Iqgen-X do?

Alivus Life Sciences acquired a 76% stake in Iqgen-X, an Indian pharmaceuticals business, for Rs 9.12 crore. The transaction is listed in PrivateCircle's August 2026 India acquisition roundup, drawn from company deal disclosures.

What other Pharmaceuticals companies has Alivus Life Sciences acquired?

Iqgen-X is Alivus Life Sciences's only publicly tracked acquisition in Pharmaceuticals so far.

Read the full article →

More Pharmaceuticals acquisitions